Table 2.
Use of opioids in month before entry to study to receive transdermal fentanyl and sustained release oral morphine
| Opioid | No of patients taking drug | No (%) of patients randomised to treatment
|
|
|---|---|---|---|
| Morphine then fentanyl (n=130) | Fentanyl then morphine (n=126) | ||
| Morphine | 194 | 103 (79) | 91 (72) |
| Codeine | 19 | 8 (6) | 11 (9) |
| Buprenorphine | 18 | 10 (8) | 8 (6) |
| Ketobemidone | 18 | 8 (6) | 10 (8) |
| Oxycodone | 15 | 8 (6) | 7 (6) |
| Methadone | 7 | 5 (4) | 2 (2) |
| Dextropropoxyphene | 7 | 3 (2) | 4 (3) |
| Anileridine | 5 | 2 (2) | 3 (2) |
| Dipipanone | 5 | 1 (1) | 4 (3) |
| Fentanyl | 5 | 1 (1) | 4 (3) |
| Dihydrocodeine | 5 | 2 (2) | 3 (2) |
| Pethidine | 4 | 1 (1) | 3 (2) |
| Dextromoramide | 4 | 3 (2) | 1 (1) |
| Nicomorphine | 2 | 1 (1) | 1 (1) |
| Pentazocine | 2 | 0 | 2 (2) |
| Tilidine | 2 | 1 (1) | 1 (1) |
| Hydromorphone | 2 | 1 (1) | 1 (1) |
| Tramadol | 1 | 1 (1) | 0 |